Literature DB >> 11488773

Effects of adrenomedullin on angiotensin II stimulated atrial natriuretic peptide and arginine vasopressin secretion in healthy humans.

M C Petrie1, J E McDonald, C Hillier, J J Morton, J J McMurray.   

Abstract

AIMS: Adrenomedullin is a newly described peptide that has widespread tissue distribution. Its presence in cardiovascular (including vascular endothelial cells, smooth muscle cells, and cardiac atria and ventricles) and renal tissues, together with its vasodilatory and natriuretic properties, suggest a role in blood pressure regulation and fluid and electrolyte balance.
METHODS: Nine normal volunteers were studied to determine whether or not adrenomedullin influenced plasma atrial natriuretic peptide and arginine vasopressin concentrations during systemic angiotensin II infusion.
RESULTS: A significant (P = 0.02) augmentation of atrial natriuretic peptide concentrations, but no suppression of arginine vasopressin concentrations, was found with coinfusion of adrenomedullin and angiotensin II when compared with vehicle and angiotensin II.
CONCLUSIONS: Despite its vasodilator and natriuretic action, adrenomedullin significantly augmented angiotensin II-stimulated plasma atrial natriuretic peptide concentrations in healthy humans. This provides further evidence of a synergistic interaction between adrenomedullin and atrial natriuretic peptide and suggests that adrenomedullin may have a role in fluid and electrolyte balance and blood pressure regulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11488773      PMCID: PMC2014530          DOI: 10.1046/j.0306-5251.2001.01428.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Beneficial hemodynamic and renal effects of adrenomedullin in an ovine model of heart failure.

Authors:  M T Rademaker; C J Charles; L K Lewis; T G Yandle; G J Cooper; D H Coy; A M Richards; M G Nicholls
Journal:  Circulation       Date:  1997-09-16       Impact factor: 29.690

2.  Adrenomedullin stimulates cAMP accumulation and inhibits atrial natriuretic peptide gene expression in cardiomyocytes.

Authors:  A Sato; B J Canny; D J Autelitano
Journal:  Biochem Biophys Res Commun       Date:  1997-01-13       Impact factor: 3.575

3.  Effects of angiotensin II on arginine-vasopressin in physiological and pathological situations in man.

Authors:  P L Padfield; J J Morton
Journal:  J Endocrinol       Date:  1977-08       Impact factor: 4.286

4.  Intracerebroventricular injection of adrenomedullin inhibits vasopressin release in conscious rats.

Authors:  H Yokoi; H Arima; T Murase; K Kondo; Y Iwasaki; Y Oiso
Journal:  Neurosci Lett       Date:  1996-09-20       Impact factor: 3.046

5.  The role of plasma osmolality, angiotensin II and dopamine in vasopressin release in man.

Authors:  J J Morton; J M Connell; M J Hughes; G C Inglis; E C Wallace
Journal:  Clin Endocrinol (Oxf)       Date:  1985-08       Impact factor: 3.478

6.  Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin.

Authors:  O Lisy; M Jougasaki; J A Schirger; H H Chen; P T Barclay; J C Burnett
Journal:  Am J Physiol       Date:  1998-09

7.  Increased plasma levels of adrenomedullin in patients with heart failure.

Authors:  T Nishikimi; Y Saito; K Kitamura; T Ishimitsu; T Eto; K Kangawa; H Matsuo; T Omae; H Matsuoka
Journal:  J Am Coll Cardiol       Date:  1995-11-15       Impact factor: 24.094

8.  Adrenomedullin suppresses atrial natriuretic factor (ANF) secretion from isolated atrium.

Authors:  S Kaufman; Y Deng
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

9.  Radio-immunoassay for plasma alpha human atrial natriuretic peptide: a comparison of direct and pre-extracted methods.

Authors:  A M Richards; G Tonolo; G D McIntyre; B J Leckie; J I Robertson
Journal:  J Hypertens       Date:  1987-04       Impact factor: 4.844

10.  The effects of angiotensin II on circulating levels of natriuretic peptides.

Authors:  R I Cargill; W J Coutie; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1994-08       Impact factor: 4.335

View more
  6 in total

Review 1.  The dark side of the kidney in cardio-renal syndrome: renal venous hypertension and congestive kidney failure.

Authors:  Pierpaolo Di Nicolò
Journal:  Heart Fail Rev       Date:  2018-03       Impact factor: 4.214

2.  Haemodynamic, endocrine and renal actions of adrenomedullin 5 in an ovine model of heart failure.

Authors:  Miriam T Rademaker; Christopher J Charles; M Gary Nicholls; A Mark Richards
Journal:  Clin Sci (Lond)       Date:  2012-05       Impact factor: 6.124

Review 3.  Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases.

Authors:  Toshihiro Kita; Kazuo Kitamura
Journal:  Hypertens Res       Date:  2022-01-06       Impact factor: 5.528

4.  Development of Long-Acting Human Adrenomedullin Fc-Fusion Proteins.

Authors:  Sayaka Nagata; Motoo Yamasaki; Nobuko Kuroishi; Kazuo Kitamura
Journal:  Biology (Basel)       Date:  2022-07-19

5.  Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction.

Authors:  Kieran F Docherty; Ross T Campbell; Katriona J M Brooksbank; John G Dreisbach; Paul Forsyth; Rosemary L Godeseth; Tracey Hopkins; Alice M Jackson; Matthew M Y Lee; Alex McConnachie; Giles Roditi; Iain B Squire; Bethany Stanley; Paul Welsh; Pardeep S Jhund; Mark C Petrie; John J V McMurray
Journal:  Circulation       Date:  2021-05-13       Impact factor: 29.690

6.  Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failure.

Authors:  Henrike Arfsten; Georg Goliasch; Philipp E Bartko; Suriya Prausmüller; Georg Spinka; Anna Cho; Johannes Novak; Helmuth Haslacher; Guido Strunk; Joachim Struck; Martin Hülsmann; Noemi Pavo
Journal:  Br J Clin Pharmacol       Date:  2020-07-20       Impact factor: 3.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.